Brief: Intelgenx Announces FDA Approval Of Rizafilm® For The Treatment Of Acute Migraine
17/04/2023 13:16
April 17 (Reuters) - Intelgenx Technologies Corp
IGX.TO :
* INTELGENX ANNOUNCES FDA APPROVAL OF RIZAFILM® FOR THE
TREATMENT
OF ACUTE MIGRAINE
Source text for Eikon: ID:nGNXHYVpJ
Further company coverage: IGX.TO
Recent news on Intelgenx Technologies
See all newsBrief: Intelgenx Obtains Court-Approval Of Sale & Investment Solicitation Process
Brief: Intelgenx Initiates Restructuring Proceedings Under CCAA To Implement Review Of Its Strategic Alternatives
Brief: Intelgenx Initiates Restructuring Proceedings Under The CCAA
Brief: IntelGenx Says First Parkinson’s Disease Patients Dosed With Montelukast VersaFilm in Mid-Stage Clinical Trial
Brief: IntelGenx Updates Status Of Buprenorphine Buccal Film ANDA